Your browser doesn't support javascript.
loading
Factors Having an Impact on Relapse and Survival in Transplant Recipients With Alcohol-Induced Liver Disease.
Schneekloth, Terry D; Arab, Juan P; Simonetto, Douglas A; Petterson, Tanya M; Niazi, Shehzad K; Hall-Flavin, Daniel K; Karpyak, Victor M; Kolla, Bhanu P; Roth, James E; Kremers, Walter K; Rosen, Charles B.
Affiliation
  • Schneekloth TD; Department of Psychiatry & Psychology, Mayo Clinic, Scottsdale, AZ.
  • Arab JP; Department of Gastroenterology and Hepatology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Simonetto DA; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
  • Petterson TM; William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
  • Niazi SK; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
  • Hall-Flavin DK; Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL.
  • Karpyak VM; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
  • Kolla BP; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
  • Roth JE; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN.
  • Kremers WK; Allina Health, Minneapolis, MN.
  • Rosen CB; William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
Mayo Clin Proc Innov Qual Outcomes ; 5(6): 1153-1164, 2021 Dec.
Article de En | MEDLINE | ID: mdl-34938953
ABSTRACT

OBJECTIVE:

To assess the impact of standardized pretransplant alcohol abstinence and treatment guidelines on liver transplant outcomes.

METHODS:

This study assessed the posttransplant relapse and survival associated with a pretransplant guideline mandating alcohol abstinence, addiction treatment, and Alcoholics Anonymous (AA) attendance. This retrospective cohort study included liver recipients with alcohol-induced liver disease transplanted between January 1, 2000, and December 31, 2012, at a Midwest transplant center. Cox regression models tested for associations between pretransplant treatment, demographic and clinical characteristics, and outcome measures.

RESULTS:

Of 236 liver recipients (188 [79.7%] male; 210 [89%] white; mean follow-up, 88.6±55.0 months), 212 (90.2%) completed pretransplant treatment and 135 (57.2%) attended AA weekly. At 5 years, 16.3% and 8.2% had relapsed to any alcohol use and to high-dose drinking, respectively. Smoking during the 6 months before transplant was associated with any relapse (P=.0002) and high-dose relapse (P<.0001), and smoking at transplant was associated with death (P=.001). High-dose relapse was associated with death (hazard ratio, 3.5; P<.0001).

CONCLUSION:

A transplant center with a guideline requiring abstinence, treatment, and AA participation experienced lower posttransplant relapse rates from those previously reported in comparable large US transplant programs. Smoking cessation may further improve posttransplant outcomes.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Langue: En Journal: Mayo Clin Proc Innov Qual Outcomes Année: 2021 Type de document: Article Pays d'affiliation: Azerbaïdjan

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Langue: En Journal: Mayo Clin Proc Innov Qual Outcomes Année: 2021 Type de document: Article Pays d'affiliation: Azerbaïdjan